Clinical Trial Detail

NCT ID NCT01256398
Title Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements no
Sponsors National Cancer Institute (NCI)
Indications

acute lymphocytic leukemia

Therapies

Dexamethasone

Dasatinib

Tacrolimus

Cyclophosphamide + Fludarabine

Filgrastim

Mercaptopurine + Methotrexate + Vincristine

Melphalan

Cytarabine + Daunorubicin + Etoposide

Pegfilgrastim

Alemtuzumab

Leucovorin

Age Groups: adult

No variant requirements are available.